Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks Research

Zacks Research lowered shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks.com reports.

VRCA has been the subject of several other research reports. upgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Thursday, December 18th. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Loop Capital set a $17.00 target price on shares of Verrica Pharmaceuticals in a research report on Thursday, December 18th. Finally, TD Cowen reissued a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Verrica Pharmaceuticals currently has an average rating of “Reduce” and a consensus target price of $17.00.

Verrica Pharmaceuticals Trading Up 0.2%

NASDAQ:VRCA opened at $5.83 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. The firm has a market cap of $100.16 million, a price-to-earnings ratio of -3.69 and a beta of 1.42. Verrica Pharmaceuticals has a 52 week low of $3.28 and a 52 week high of $9.82. The firm has a 50-day moving average price of $5.76 and a two-hundred day moving average price of $5.91.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Wednesday, March 11th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The business had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $4.52 million. On average, equities analysts expect that Verrica Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Man Group plc bought a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at approximately $94,000. Quadrature Capital Ltd bought a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $99,000. Beck Mack & Oliver LLC bought a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $100,000. Bridgeway Capital Management LLC bought a new position in Verrica Pharmaceuticals in the 3rd quarter worth approximately $52,000. Finally, XTX Topco Ltd bought a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $122,000. 42.45% of the stock is owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.